Subjects must have received at least  and not more than  previous lines of treatment and have had a response to at least  prior Treatment in the past (i.e., achieved a minimal response [MR] or better) according to the IMWG uniform response criteria.
Subjects must have documented evidence of progressive disease according to the IMWG uniform response criteria following the last multiple myeloma treatment.
Documented major response [partial response (PR), very good partial response (VGPR), complete response (CR)] according to the International Myeloma Working Group (IMWG) uniform response criteria, version , after this initial therapy.
Completion of induction therapy with very good partial response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria
On treatment with ruxolitinib for at least  months and have been on a stable dose for at least  weeks and have not achieved a complete response (CR) by International Working Group (IWG) criteria
Complete or partial response to salvage chemotherapy by International Working Group (IWG) criteria
Evidence of a response (Partial response [PR] or better based on investigator's determination of response by international myeloma working group [IMWG] criteria) to at least  prior treatment regimen
Complete or partial response by International Working Group (IWG) Working Group or International Conference on Malignant Lymphoma (ICML) criteria to maximum of one salvage line of chemotherapy without pre-HDT/ASCT salvage radiotherapy
Subjects must have failed hypomethylating treatment where \failure\ is defined as: Progression (according to  International Working Group [IWG] criteria) at any time after initiation of the hypomethylating treatment OR Failure to achieve complete or partial response or hematological improvement (HI) (according to  IWG) after at least  cycles treatment OR Relapse after initial complete or partial response or HI (according to  IWG criteria).
Patients must have either:\r\n* Symptomatic multiple myeloma who have responded to prior induction or salvage chemotherapy (i.e. chemosensitive disease): patients who are receiving high-dose melphalan and AHCT as part of their initial therapy require at least a partial response (PR) as defined by the International Myeloma Working Group uniform response criteria for MM; patients who are receiving high-dose melphalan and AHCT as part of salvage therapy require at least a minor response to their last line of therapy to document chemosensitive disease; there is no limit on the number of prior regimens received by the patient; OR\r\n* Light chain (AL) amyloidosis who may be newly diagnosed or previously treated
Subjects with symptomatic multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria who are receiving or have completed induction chemotherapy, who have achieved at least a partial response (PR) on most recent therapy by IMWG criteria, and are eligible for auto-SCT for consolidation; a specific induction regimen is not dictated for this protocol, however, the induction regimen must not have contained melphalan (L-PAM, Alkeran)
Patients with newly diagnosed multiple myeloma who have at least a partial response after induction therapy based on the International Working Group (IWG) Uniform Response Criteria
Patients must carry a diagnosis of symptomatic multiple myeloma according to international myeloma working group criteria and have relapsed or refractory disease according to international uniform response criteria after at least two prior treatment regimens including a proteasome inhibitor and an immunomodulator (IMiD)
Must have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimen
Evidence of a response (partial response [PR] or better based on investigator's determination of response by International Myeloma Working Group [IMWG] criteria) to at least  prior treatment regimen
Measurable disease by International Working Group (IWG) response criteria for lymphoma
For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects must have histological confirmation of multiple myeloma with measurable\n             disease (per International Myeloma Working Group (IMWG) criteria):\n\n               -  Relapsed/refractory multiple myeloma, subjects who are post autologous transplant\n                  and have achieved very good partial response (VGPR) or complete response (nCR)\n                  with minimal residual disease (MRD)
Documented diagnosis of multiple myeloma, currently with complete response (CR) or very good partial response (VGPR) (as defined by International Myeloma Working Group [IMWG] criteria), at least two years after induction therapy or autologous stem cell transplant
Documented evidence of progressive MM (based on the Investigator's determination according to the modified IMWG response criteria) on or after their most recent regimen.